News
TLPH
1.400
-4.76%
-0.070
Here are the major earnings after the close Wednesday
Seeking Alpha · 18h ago
Weekly Report: what happened at TLPH last week (0803-0807)?
Weekly Report · 2d ago
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
PR Newswire · 08/05 20:05
Weekly Report: what happened at TLPH last week (0727-0731)?
Weekly Report · 08/03 09:05
Weekly Report: what happened at TLPH last week (0720-0724)?
Weekly Report · 07/27 09:06
Weekly Report: what happened at TLPH last week (0713-0717)?
Weekly Report · 07/20 09:05
Weekly Report: what happened at TLPH last week (0706-0710)?
Weekly Report · 07/13 09:06
Weekly Report: what happened at TLPH last week (0629-0703)?
Weekly Report · 07/06 09:06
Weekly Report: what happened at TLPH last week (0622-0626)?
Weekly Report · 06/29 09:06
Talphera Shareholders Approve Directors and Governance Proposals
TipRanks · 06/23 21:20
Weekly Report: what happened at TLPH last week (0615-0619)?
Weekly Report · 06/22 09:06
Weekly Report: what happened at TLPH last week (0608-0612)?
Weekly Report · 06/15 09:06
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 06/08 17:06
Weekly Report: what happened at TLPH last week (0601-0605)?
Weekly Report · 06/08 09:06
Dollar Tree, Onto, Chipotle, Lululemon, Talphera Trending
TipRanks · 06/06 09:01
Talphera Price Target Announced at $3.00/Share by HC Wainwright & Co.
Dow Jones · 06/05 12:51
Talphera Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 06/05 12:51
HC Wainwright & Co. Assumes Talphera at Buy, Announces Price Target of $3
Benzinga · 06/05 12:42
Talphera assumed with a Buy at H.C. Wainwright
TipRanks · 06/05 10:27
Weekly Report: what happened at TLPH last week (0525-0529)?
Weekly Report · 06/01 09:06
More
Webull provides a variety of real-time TLPH stock news. You can receive the latest news about Talphera Inc through multiple platforms. This information may help you make smarter investment decisions.
About TLPH
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.